CABA

In a report released on August 11, Geulah Livshits from Chardan Capital reiterated a Buy rating on Cabaletta Bio (CABA - Research Report), with a price target of $13.00. The company's shares closed last Friday at $1.53.According to TipRanks, Livshits is a 5-star analyst with an average return of 28.5% and a 45.25% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Meiragtx Holdings, and Iovance Biotherapeutics.Cabaletta Bio has an analyst consensus of Strong Buy, with a price target consensus of $11.33, a 640.52% upside from current levels.
https://www.tipranks.com/news/blurbs/chardan-capital-keeps-their-buy-rating-on-cabaletta-bio-caba?utm_source=advfn.com&utm_medium=referral